‘Kinder’ treatment for childhood brain cancer to be offered by NHS in England
Dabrafenib with trametinib can halt growth of some tumours for more than three times as long as standard chemotherapy, study showsThe NHS is to offer children with brain tumours in England a groundbreaking new targeted drug therapy to tackle the disease – a development charities are hailing as the biggest breakthrough in decades.Gliomas are the most common type of brain cancer in children but experts say the standard treatment of chemotherapy can be brutal and gruelling, and also carries the risk of side-effects such as weight loss, seizures and headaches.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 24, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer Children's health National Institute for Health and Care Excellence England NHS UK news Society Medical research Science Source Type: news
New Targeted Drug Approved for Low-Grade Glioma in Kids
(MedPage Today) -- The FDA granted accelerated approval to tovorafenib (Ojemda) for children 6 months and up with relapsed or refractory low-grade glioma and BRAF-altered tumors, the agency announced on Tuesday.
It represents the first systemic... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 24, 2024 Category: American Health Source Type: news
FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutati (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 23, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
PET tracer for gliomas under expedited review
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Telix Pharmaceuticals’ PET radiotracer F-18 floretyrosine (Pixclara) for imaging progressive or recurring gliomas.
Pixclara was developed by researchers at the University of California, San Francisco. The tracer reveals the activity of specific transporter proteins known as LAT1 and LAT2, which are highly active in brain regions with gliomas. The technique can help determine if a glioma is truly progressing or undergoing a treatment-induced change, known as pseudo-progression, where standard MRI is often inconclusive, the company said.
Pi...
Source: AuntMinnie.com Headlines - April 17, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Molecular Imaging Source Type: news
French-led team unveils 11.7 tesla MRI scans of human brain
A research group based in Saclay, near Paris, has taken the wraps off what it claims are the world's first MRI scans of the human brain in vivo taken at a field strength of 11.7 tesla. President Emmanuel Macron has congratulated the researchers on social media.
"The first images surpassed our expectations, giving after just four minutes, mind-blowing brain images without any artifacts, with superb tissue contrast and resolution, which represents a volume equivalent to a few thousand neurons," Denis Le Bihan, PhD, founding director of the NeuroSpin research facility and founder of Iseult Project of the French Alternative E...
Source: AuntMinnie.com Headlines - April 4, 2024 Category: Radiology Authors: Philip Ward Tags: MRI Source Type: news
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
Boston, MA, Suresnes, France, February 20 2024– Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA filing acceptance and priority review for a New... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 20, 2024 Category: Drugs & Pharmacology Source Type: news
AI spots unidentified brain tumor on PET imaging
An AI algorithm designed for brain PET imaging found a glioblastoma in a patient that had gone undetected by physicians, according to a case reported February 15 in the Journal of Nuclear Medicine.“This incidental finding highlights the potential of AI-based decision support for patient management in terms of diagnostic and treatment planning based on amino acid PET,” noted lead author Philipp Lohmann, PhD, of Aachen University in Aachen, and colleagues.In brief, the deep learning-based AI model (called “JuST_BrainPET”) is designed to automatically segment metabolic tumor volume (MTV) from surrounding healthy tissu...
Source: AuntMinnie.com Headlines - February 19, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Neuroradiology Source Type: news
Targeting IDH Mutated Glioma: A Decade ’s Journey from Bench to Bedside. Targeting IDH Mutated Glioma: A Decade ’s Journey from Bench to Bedside.
Prof Tim Cloughesy reviews the key early development milestones that lead to the evaluation of Vorasidenib in the INDIGO trial.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Management of IDH-Mutated Gliomas in Germany Management of IDH-Mutated Gliomas in Germany
Learn how expert referral centres optimise treatment for their glioma patientsMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Navigating the Paradigm Shift: A New Era of Glioma Care. Navigating the Paradigm Shift: A New Era of Glioma Care.
Hear Prof Ghazaleh Tabatabai discuss how new clinical data and the application of ‘Personalised Treatment Strategies’ is impacting the care of glioma patients.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
PHILADELPHIA, Dec. 18, 2023 -- (Healthcare Sales & Marketing Network) -- On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being devel... Regenerative Medicine, Neurosurgery, Oncology, FDA NeuExcell Therapeutics, malignant glioma, gene therapy, glioblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2023 Category: Pharmaceuticals Source Type: news
Hear firsthand how patients with IDH-mutated gliomas can receive personalised therapy Hear firsthand how patients with IDH-mutated gliomas can receive personalised therapy
A capsule of the progress in treating IDH mutant gliomasMedscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
‘Tiny Pretty Things’ Actor Barton Cowperthwaite Diagnosed With Stage 2 Glioma; Plans To Undergo Brain Surgery To Remove Tumor
Barton Cowperthwaite, star of Netflix’s Tiny Pretty Things, is opening up about his health and revealed he was diagnosed with Stage 2 brain cancer. The actor in the streaming series said that he plans to undergo surgery to remove the brain tumor. “So…. Yesterday I was diagnosed with at least a…#bartoncowperthwaite #netflix #tinyprettythings #2glioma #cowperthwaite #docs #orenlennox #michaelmaclennan #sonacharaipotra #dhonielleclayton (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2023 Category: Consumer Health News Source Type: news
Mapping cell behaviors in high-grade glioma to improve treatment
The researchers profiled 313 tumor biopsies from 68 high-grade glioma (HGG) patients. This image is a representation of the 3-dimensional relationship of multiple tissue biopsies from a single patient ’s HGG tumor. The different colors depict different versions of genetic mutations relative to the epidermal growth factor receptor gene. High-grade gliomas are cancerous tumors that spread quickly in the brain or spinal cord. In a new study led by Mayo Clinic, researchers found invasive brain tumo r… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 10, 2023 Category: Databases & Libraries Source Type: news
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the“Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 30, 2023 Category: Drugs & Pharmacology Source Type: news
